CELU NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Celularity Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 0.75 USD
-3.9% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -28.9% below the Trend Line and sits at 5.1% of its 52-week range. The latest completed week returned -3.9%, after a 21.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is mixed with 25/100 conviction, while the latest news-sentiment score is 46/100. Near-term considerations: volume confirmation is below normal; earnings are due in 36d.

Setup score 24 out of 100
Latest Close 0.75 USD 24 Jul 2026
1W Return -3.9% latest completed week
4W Return 21.0% short-term follow-through
12W Return -21.6% quarterly tape
Trend Breadth 17.3% 9 of 52 weeks active
Volume Ratio 0.2x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -3.9% Latest completed week; four-week move 21.0%. Indicator stack 10/43 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 42.52% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Mixed 25/100 conviction; expected move 240.0%. News sentiment 46/100 58 relevant articles in the latest sentiment read. Event risk 36d Next report is scheduled for 04 Sep 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -28.9% below the Trend Line and sits at 5.1% of its 52-week range. The latest completed week returned -3.9%, after a 21.0% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.2x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0212-week average 0.02

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.02Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 21.0% over four weeks, -21.6% over 12 weeks, and -74.7% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-3.9%
4W21.0%
12W-21.6%
26W-41.9%
52W-74.7%
Active trend streak0 weeks
Active weeks in one year9
Trend breadth17.3%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.51Latest activity-pressure read.
Pressure change25.6%Four-week change in activity pressure.
Leadership-57.77Latest relative-leadership reading.
RS change16.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 76% Model confidence 73%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength68/100Blend of value, momentum, and quality. Underlying universe rank 33; rank 1 is best.
Value58/100Relative valuation strength. Underlying universe rank 43; rank 1 is best.
Quality57/100Profitability and accounting quality. Underlying universe rank 44; rank 1 is best.
Momentum58/100Medium-term price momentum. Underlying universe rank 43; rank 1 is best.
Growth58/100Revenue and earnings growth. Underlying universe rank 43; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
1.1x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-27.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
47.0%
Gross profit retained from each unit of revenue.
Operating margin
-466.5%
Operating profit retained from revenue.
Free-cash-flow margin
-79.6%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-66.7%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
27.2%
Cash dividends relative to market value.
Buyback yield
-18.4%
Net share repurchases relative to market value.
Shareholder yield
8.8%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningMixed

CELU shows mixed options pressure with a 25/100 conviction score, put-call volume ratio of n/a, expected move of 240.0%, and Sharemaestro trend signal inactive.

Conviction25/100
Expected move240.0%
Put/call volume
Pressure11
Speculation0
Volatility96
Trend agreement40
Open options detail
Insider activity0 / 6

0 acquisitions and 6 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment46/100

Weighted news tone is neutral across 58 relevant articles.

2 positive · 44 neutral · 12 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings36dNext report is scheduled for 04 Sep 2026; event risk rises as the date approaches.
Options expected move240.0%Nearest-chain priced movement where available.
52-week drawdown-82.6%Distance below the 52-week high.
13-week volatility11.9%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher9 of 2615 weeks finished lower.
Best week+19.5%Week of 10 Jul.
Worst week-18.3%Week of 12 Jun.
Latest week-3.9%Week of 24 Jul.

Shape of recent returns

Strong gains8
Modest gains1
Flat weeks2
Modest losses5
Sharp losses10
Recent vol11.9%13-week weekly-return volatility.
Base vol10.0%52-week weekly-return volatility.
Up/down split20/30Count of positive and negative weeks in the 52-week window.
Average skew7.4% / -8.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape16/100

Trend, activity pressure, participation, and risk combine to a 16/100 tape read.

 Indicator analysis9/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.02; No reversal markers Next-Week ExpectancyNegative 42.52%

Next-week expectancy is negative with a 42.52% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors60/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 90 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options40/100

CELU shows mixed options pressure with a 25/100 conviction score, put-call volume ratio of n/a, expected move of 240.0%, and Sharemaestro trend signal inactive.

Mixed · Options-market disagreement · Expected move 240.0% Sentiment46/100

Weighted news tone is neutral across 58 relevant articles.

Celularity Inc. (CELU) warrants delisted and deregistered from Nasdaq exchange Insiders0 / 6

0 acquisitions and 6 disposals in the latest 180-day insider tape.

 Earnings36d

Next report is scheduled for 04 Sep 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20260.75 USD-3.9%1.06 USD2.34 USD-0.51-57.77167.3KOff
17 Jul 20260.78 USD5.4%1.07 USD2.37 USD-0.68-58.05188.5KOff
10 Jul 20260.74 USD19.5%1.10 USD2.40 USD-0.71-62.991.2MOff
3 Jul 20260.62 USD-0.0%1.13 USD2.42 USD-0.86-69.07212.4KOff
26 Jun 20260.62 USD-17.6%1.17 USD2.45 USD-0.69-69.36862.6KOff
19 Jun 20260.75 USD5.5%1.22 USD2.48 USD-0.53-65.08953.9KOff
12 Jun 20260.71 USD-18.3%1.25 USD2.52 USD-0.58-66.54584.7KOff
5 Jun 20260.87 USD-13.6%1.28 USD2.57 USD-0.58-58.74619.8KOff
29 May 20261.01 USD16.1%1.31 USD2.60 USD-0.62-55.16712.2KOff
22 May 20260.87 USD7.6%1.34 USD2.64 USD-0.67-60.92733.4KOff
15 May 20260.81 USD-8.1%1.38 USD2.68 USD-0.51-63.99930.9KOff
8 May 20260.88 USD-8.1%1.42 USD2.71 USD-0.19-61.58603.3KOff
1 May 20260.96 USD-13.8%1.46 USD2.74 USD0.12-56.481.8MOff
24 Apr 20261.11 USD-9.8%1.50 USD2.76 USD0.38-49.30227.7KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.